Mobile

A clinical research study to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001377-88

A clinical research study to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of subjects with at least 75% improvement in the Psoriasis Area and Severity Index from baseline (PASI 75 response) and the proportion of subjects with a Physician’s Global Assessment (PGA) score of “clear” or “minimal” with at least a 2 grade reduction from baseline at Week 12. Primary Safety/Tolerability Objective: To assess the safety/tolerability of MK-3222 in subjects with moderateto-severe chronic plaque psoriasis at Week 12.

Critère d'inclusion

  • Moderate To Severe Chronic Plaque Psoriasis

Liens